Special Offers & Promotions



Latest News



View Channel

New Products



View Channel

Video Presentations



View Channel

Separation Science



View Channel

Microscopy & Image Analysis



View Channel

Laboratory Automation & IT Solutions



View Channel


Proximagen Licenses Cresset

publication date: Dec 5, 2014
author/source: Cresset BioMolecular Discovery Ltd

Cresset, innovative provider of computational chemistry software and services, is pleased to announce that Proximagen, a company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS), has licensed Cresset’s Forge and Spark software.

cresset logoThese applications provide extensive capabilities in SAR analysis, ligand-based molecular design and bioisosteric replacement.

"Proximagen has successfully used Cresset’s computational chemistry tools in the past to generate pharmacophores from known ligands and to identify novel chemical series by scaffold hopping,” says Dr Ed Savory, Deputy Head of Chemistry at Proximagen. “We will be using Spark to identify new drug scaffolds and to make bioisosteric core replacements. Both Spark and Forge are now important and valuable components of our drug discovery program."

“We are delighted that Proximagen have chosen to further the collaboration with Cresset, says Dr David Bardsley, Cresset’s Commercial Director. “Cresset’s continual striving for outstanding science delivered in usable software is translating into valuable results for our customers.”

About Cresset

Cresset’s software and consulting services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavour, fragrance, petrochemicals and pharmaceuticals.

About Proximagen

Proximagen is a UK-based biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and is owned by Upsher-Smith Laboratories, Inc., a Minnesota-based growing pharmaceutical company.

Upsher-Smith Laboratories, Inc. founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving LifeTM. With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to developing quality products that enable people to live life to its greatest potential.

more about cresset

more news from cresset


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month



Today's Picks



Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners


Exhibitions & Events